According to Coloplast's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 42.1351. At the end of 2022 the company had a P/E ratio of 34.1.
Year | P/E ratio | Change |
---|---|---|
2022 | 34.1 | -23.2% |
2021 | 44.5 | -13.1% |
2020 | 51.2 | 14.24% |
2019 | 44.8 | 21.97% |
2018 | 36.7 | 28.71% |
2017 | 28.5 | -17.57% |
2016 | 34.6 | -67.97% |
2015 | 108 | 152.89% |
2014 | 42.7 | 75.01% |
2013 | 24.4 | 4.51% |
2012 | 23.4 | 21.05% |
2011 | 19.3 | -13.68% |
2010 | 22.4 | 8.7% |
2009 | 20.6 | -14.62% |
2008 | 24.1 | -62.28% |
2007 | 63.9 | 89.26% |
2006 | 33.8 | 7.14% |
2005 | 31.5 | 0.35% |
2004 | 31.4 | 3.98% |
2003 | 30.2 | 82.03% |
2002 | 16.6 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.